-

Dexcom Announces Upcoming Virtual Conference Presentations

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming virtual investor conferences:

  • Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present on behalf of the company at the Wells Fargo 2021 Virtual Healthcare Conference on Friday, September 10, 2021 at 2:00pm (EST).
  • Quentin Blackford, Chief Operating Officer, will present on behalf of the company at the Morgan Stanley 19th Annual Healthcare Conference on Monday, September 13, 2021 at 2:00pm (EST).

Links to the webcasts will be available on the Dexcom Investor Relations website at investors.dexcom.com/ and will be archived there for future reference.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.

Contacts

DexCom, Inc.
Sean Christensen
Senior Director – Investor Relations and Corporate FP&A
Investor-relations@dexcom.com
(858) 200-0200

Industry:

DexCom, Inc.

NASDAQ:DXCM
Release Summary
Dexcom Announces Upcoming Virtual Conference Presentations
Release Versions
English

Contacts

DexCom, Inc.
Sean Christensen
Senior Director – Investor Relations and Corporate FP&A
Investor-relations@dexcom.com
(858) 200-0200

More News From DexCom, Inc.

Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy

EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of Dexcom Academy, a new personalised learning platform created with healthcare professionals (HCPs) and for healthcare professionals. The platform is now available in Belgium, Germany, the Kingdom of Saudi Arabia, the Netherlands, and Spain with further EMEA country launches planned for 2026. Guided directly by H...

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1. At initial launch, Dexcom G7 15 Day will be available for users who receive their Dexcom CGM through DME providers. G7 15 Day will also be covered for Medicare beneficiaries and has met the category requirements for therapeutic CGM sy...

Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy.1 Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate personalized daily recommendations to guide users towards a more effective long-acting insulin dose, as...
Back to Newsroom